From Strength

to Strength
Growing steadily in scale and reach

Our Evolution

Under a decade, we have grown from a single manufacturing facility focused on the Indian market to four locations producing scores of products, approvals from multiple regulators and a global reach.

  • 2000

    Glenmark Pharmaceuticals established its API business with 2 R&D labs & 10 scientists.
    2 new API products developed in the first year.
  • 2001

    Established manufacturing facility at Kurkumbh, Maharashtra with a focus on Indian market.
  • 2002

    Acquired Glaxo SmithKline’s (GSK) API manufacturing facility in India to penetrate regulated markets for API.
    R&D Centre approved by Department of Science & Technology.
  • 2003

    First product registered with US-FDA and MHRA UK
  • 2004

    Commenced manufacturing operations at Mohol, Maharashtra.
  • 2007

    Ankleshwar plant in Gujrat inspected by US-FDA.
  • 2008

    First product registered with ANVISA.
  • 2012

    Ankleshwar plant inspected by PMDA, EDQM and COFEPRIS.
  • 2013

    Commenced manufacturing at Dahej, Gujrat.
  • 2015

    Dahej plant inspected by US-FDA and PMDA.
  • 2017

    Mohol manufacturing facility inspected by US-FDA.
    260+ inventions.
  • 2018

    Dahej plant inspected by EDQM and US-FDA
    Over 380+ Drug Master Files (DMFs) filed in various markets.
  • 2019

    Glenmark transferred the API business to a wholly-owned subsidiary Glenmark Life Sciences
    Ankleshwar plant inspected by US-FDA and Health Canada